Stockscreener 앱 받기
79.44
3.28%
2.52
전일 마감가:
$76.92
열려 있는:
$77.83
하루 거래량:
1.72M
Relative Volume:
0.83
시가총액:
$9.34B
수익:
$947.36M
순이익/손실:
$392.47M
주가수익비율:
26.30
EPS:
3.02
순현금흐름:
$392.71M
1주 성능:
-2.20%
1개월 성능:
+10.84%
6개월 성능:
+21.97%
1년 성능:
+35.54%
1일 변동 폭
$77.55
$81.19
1주일 범위
$76.10
$82.22
52주 변동 폭
$47.50
$82.22
Halozyme Therapeutics Inc Stock (HALO) Company Profile
명칭
Halozyme Therapeutics Inc
전화
(858) 794-8889
주소
12390 EL CAMINO REAL, SAN DIEGO, CA
Compare HALO vs VRTX, REGN, ARGX, ALNY, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
HALO
Halozyme Therapeutics Inc
|
79.44 | 9.05B | 947.36M | 392.47M | 392.71M | 3.02 |
|
VRTX
Vertex Pharmaceuticals Inc
|
491.47 | 117.98B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.17 | 82.85B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
821.96 | 51.58B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.40 | 40.75B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.07 | 38.33B | 4.98B | 69.60M | 525.67M | 0.5198 |
Halozyme Therapeutics Inc Stock (HALO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-12-04 | 다운그레이드 | Goldman | Neutral → Sell |
| 2025-10-14 | 업그레이드 | Leerink Partners | Underperform → Market Perform |
| 2025-08-06 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-10 | 재개 | Goldman | Neutral |
| 2025-05-14 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2025-05-13 | 다운그레이드 | Leerink Partners | Market Perform → Underperform |
| 2024-10-07 | 다운그레이드 | Wells Fargo | Overweight → Equal Weight |
| 2024-09-19 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2024-06-07 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-02-29 | 개시 | TD Cowen | Outperform |
| 2023-07-24 | 다운그레이드 | Goldman | Buy → Neutral |
| 2023-07-24 | 개시 | H.C. Wainwright | Buy |
| 2023-05-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-03-27 | 재개 | Berenberg | Buy |
| 2023-03-16 | 다운그레이드 | SVB Securities | Outperform → Market Perform |
| 2022-12-21 | 재개 | Morgan Stanley | Overweight |
| 2022-11-28 | 개시 | Wells Fargo | Overweight |
| 2022-09-09 | 개시 | Morgan Stanley | Overweight |
| 2022-05-23 | 개시 | SVB Leerink | Outperform |
| 2021-06-14 | 개시 | Evercore ISI | Outperform |
| 2021-05-17 | 개시 | SVB Leerink | Outperform |
| 2021-05-11 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-01-21 | 재확인 | The Benchmark Company | Buy |
| 2020-12-17 | 개시 | Berenberg | Buy |
| 2020-09-14 | 재개 | JP Morgan | Overweight |
| 2020-07-01 | 개시 | The Benchmark Company | Buy |
| 2020-02-05 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2020-01-09 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2020-01-08 | 개시 | Goldman | Buy |
| 2019-11-05 | 업그레이드 | Barclays | Underweight → Equal Weight |
| 2018-10-19 | 재개 | Piper Jaffray | Neutral |
| 2018-05-11 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2018-01-24 | 개시 | Goldman | Neutral |
| 2017-10-16 | 재확인 | Piper Jaffray | Overweight |
| 2017-01-06 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2016-11-03 | 개시 | Deutsche Bank | Buy |
| 2015-12-04 | 개시 | Wells Fargo | Outperform |
| 2015-11-18 | 개시 | Citigroup | Buy |
| 2015-09-22 | 개시 | Barclays | Overweight |
| 2015-06-22 | 재확인 | JP Morgan | Overweight |
| 2015-03-03 | 재확인 | UBS | Buy |
| 2015-02-18 | 재확인 | MLV & Co | Buy |
| 2015-01-08 | 재확인 | MLV & Co | Buy |
모두보기
Halozyme Therapeutics Inc 주식(HALO)의 최신 뉴스
Acadia Healthcare, Hims & Hers Health, RadNet, Halozyme Therapeutics, and Privia Health Shares Are Soaring, What You Need To Know - The Globe and Mail
Halozyme Biotech Acquisitions And M&A Plan Weigh On Valuation Case - Sahm
Halozyme Startup Deals Recast Growth Plan And Raise Valuation Questions - Yahoo Finance
Stay Ahead of the Game With Halozyme Therapeutics (HALO) Q4 Earnings: Wall Street's Insights on Key Metrics - Yahoo Finance
ING Groep NV Acquires New Stake in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Will Halozyme Therapeutics Inc. benefit from rate cutsPortfolio Return Report & Scalable Portfolio Growth Methods - mfd.ru
Halozyme to Report Fourth Quarter and Full Year 2025 Financial and Operating Results - The Malaysian Reserve
Halozyme Therapeutics (HALO) to Report Q4 Results: Wall Street Expects Earnings Growth - Finviz
Biotech: Halozyme CEO explains what it looks for in M&A targets - Yahoo Finance
Profund Advisors LLC Trims Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (HALO) to Release Earnings on Tuesday - MarketBeat
Halozyme Expecting Decade of Growth - San Diego Business Journal
New York State Common Retirement Fund Sells 3,399,839 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Renaissance Group LLC Invests $35.11 Million in Halozyme Therapeutics, Inc. $HALO - MarketBeat
Assessing Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Sahm
Halozyme Therapeutics stock hits all-time high at 79.99 USD By Investing.com - Investing.com Nigeria
Halozyme Therapeutics (NASDAQ:HALO) Hits New 12-Month HighTime to Buy? - MarketBeat
Halozyme Therapeutics stock hits all-time high at 79.99 USD - Investing.com
A Look At Halozyme Therapeutics (HALO) Valuation After Raised 2025 And 2026 Revenue Guidance - Yahoo Finance
Halozyme Therapeutics, Inc. $HALO Shares Acquired by Thrivent Financial for Lutherans - MarketBeat
Helen Torley Sells 20,000 Shares of Halozyme Therapeutics (NASDAQ:HALO) Stock - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) CEO Sells 10,000 Shares - MarketBeat
Halozyme, Other Hot Medical Plays Lead 22 Stocks Onto Best Stock Lists Like IBD 50, IPO Leaders - Investor's Business Daily
Halozyme’s Drug-Delivery Royalties Are Driving A Rerating Case - Finimize
BI Asset Management Fondsmaeglerselskab A S Sells 155,995 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Hantz Financial Services Inc. Has $7.18 Million Stock Holdings in Halozyme Therapeutics, Inc. $HALO - MarketBeat
2 Under-the-Radar Biotech Stocks Set to Boom in 2026 - AOL.com
Why Halozyme Therapeutics (HALO) is a Top Value Stock for the Long-Term - Yahoo Finance
Zacks Research Has Positive Outlook of HALO FY2025 Earnings - MarketBeat
Benchmark maintains Buy rating on Halozyme stock amid raised guidance By Investing.com - Investing.com Canada
Q1 EPS Estimate for Halozyme Therapeutics Raised by Analyst - MarketBeat
Halozyme Therapeutics (HALO) Is Up 6.6% After Lifting Guidance And Expanding ENHANZE Beyond Oncology - Sahm
Strs Ohio Sells 25,069 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics: Key Acquisitions To Help Drive Long-Term Growth - Seeking Alpha
Halozyme Therapeutics, Inc. (HALO) Stock Analysis: Uncovering A 8.77% Upside Potential - DirectorsTalk Interviews
(HALO) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Why This Stock Of The Day Is Story Of 'Layering And Duration' - Investor's Business Daily
Will Halozyme Therapeutics (HALO) Beat Estimates Again in Its Next Earnings Report? - Finviz
Merck gains U.S. patent office support in Keytruda dispute - MSN
Halozyme Therapeutics, Inc. $HALO Shares Sold by Y Intercept Hong Kong Ltd - MarketBeat
What Halozyme Therapeutics (HALO)'s Upgraded Revenue Outlook and ENHANZE Acquisitions Strategy Means For Shareholders - Yahoo Finance
Is Halozyme Therapeutics (HALO) Still Attractive After Recent Drug Delivery Partnership-Driven Gains - Sahm
AlphaQuest LLC Acquires 34,011 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
Halozyme Therapeutics (NASDAQ:HALO) Raised to Strong-Buy at Wall Street Zen - MarketBeat
Why Halozyme Therapeutics (HALO) is a Top Momentum Stock for the Long-Term - Yahoo Finance
Setup Watch: Is Halozyme Therapeutics Inc forming a breakout patternDip Buying & AI Optimized Trading Strategy Guides - baoquankhu1.vn
If You Invested $1000 in Halozyme Therapeutics a Decade Ago, This is How Much It'd Be Worth Now - Yahoo Finance
Q4 EPS Forecast for Halozyme Therapeutics Lifted by Analyst - MarketBeat
Great Lakes Advisors LLC Sells 14,747 Shares of Halozyme Therapeutics, Inc. $HALO - MarketBeat
A Look At Halozyme Therapeutics (HALO) Valuation After Raised Guidance And Drug Delivery Acquisitions - Sahm
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating - Finviz
Halozyme Therapeutics Inc (HALO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Halozyme Therapeutics Inc 주식 (HALO) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Torley Helen | PRESIDENT AND CEO |
Feb 04 '26 |
Option Exercise |
12.07 |
20,000 |
241,400 |
728,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 05 '26 |
Option Exercise |
12.07 |
10,000 |
120,700 |
718,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 04 '26 |
Sale |
77.24 |
20,000 |
1,544,820 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 03 '26 |
Sale |
76.12 |
20,000 |
1,522,317 |
708,719 |
| Torley Helen | PRESIDENT AND CEO |
Feb 05 '26 |
Sale |
78.64 |
10,000 |
786,366 |
708,719 |
1.12%
0.87%
자본화:
|
볼륨(24시간):